Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02193815 | A 12 Day Study To Evaluate A Topical Drug To Treat Plaque Psoriasis | PHASE1 | COMPLETED | 15 | — | — | Sep 1, 2014 | Feb 1, 2015 | Jun 9, 2016 | 1 | Germany |
Psoriatic skin thickness was measured using a 20 megahertz (MHz) high frequency sonograph. Serial A-scans were composed and presented on a monitor as a section of the skin.
| Arm | Type | Description |
|---|---|---|
| One Arm | EXPERIMENTAL | Study treatments 1-6 Study drug, vehicle, Tofacitinib, vehicle, Daivonex solution and ointment |
| Name | Type | Description |
|---|---|---|
| PF06263276 | DRUG | 4% PF 06263276 solution Daily dosage: approximately 8 mg PF 06263276 QD |
| Vehicle | OTHER | Active ingredient-free vehicle to 4% solution |
| 2%Tofacitinib Ointment | DRUG | Daily Dosage: approximately 4 mg tofacitinib |
| Daivonex | DRUG | Daivonex solution (50 ug/ml Calcipotriol) Daily Dosage of calcipotriol: approximately 0.01 mg |
| Daivonex Ointment | DRUG | Daivonex ointment (50 ug/g Calcipotriol) Daily Dosage of calcipotriol: approximately 0.01 mg |
Inclusion Criteria: * Healthy male and/or female subjects age 18 years and older, inclusive. Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12 lead ECG or clinical l...